Ciprofloxacin, a fluoroquinolone antibiotic, targets bacterial DNA gyrase and topoisomerase IV. These enzymes are crucial for bacterial DNA replication, transcription, and repair. By inhibiting these enzymes, ciprofloxacin prevents bacterial cell division and growth, leading to bacterial death.
The drug’s mechanism involves binding to these enzymes, preventing them from functioning correctly. This disruption halts the essential processes of DNA supercoiling and unwinding needed for DNA replication, causing bacterial DNA damage and ultimately cell death. Different bacterial species exhibit varying sensitivities to ciprofloxacin, depending on the specific structure and function of their gyrases and topoisomerases.
Absorption of ciprofloxacin varies based on the administration route (oral or intravenous). Oral administration leads to a slower onset of action compared to intravenous administration. This difference impacts treatment timing and efficacy. Metabolism and elimination occur primarily through renal excretion, influencing dosage adjustments in patients with kidney impairment.
Ciprofloxacin’s impact on mitochondrial DNA gyrase in human cells contributes to side effects, including fatigue. While it’s more potent against bacterial enzymes, some interaction with human mitochondrial DNA is possible. This explains why some individuals experience fatigue as a side effect, although the exact mechanisms and individual susceptibility remain areas of ongoing research.
